Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
To examine a possible association between debrisoquine 4-hydroxylase gene mutations and neuroleptic malignant syndrome, we assessed frequencies of wild type and A and B mutant alleles of the CYP2D6 gene in 24 patients with a history of neuroleptic malignant syndrome, 50 patients with neuroleptic-treated schizophrenia but no history of neuroleptic malignant syndrome, and 50 healthy controls. Allele frequencies did not differ significantly between these groups. Homozygotes for CYP2D6A and for CYP2D6B, which indicate a poor-metabolizer phenotype for the CYP2D6 substrate, were not detected among the neuroleptic malignant syndrome cases. This result indicates no excess of poor CYP2D6 metabolizers in neuroleptic malignant syndrome. The aetiology of neuroleptic malignant syndrome is not explainable in terms of CYP2D6 gene mutations.
Kawanishi
C
C
Department of Psychiatry, Yokohama City University School of Medicine, Japan.
Hanihara
T
T
Maruyama
Y
Y
Matsumura
T
T
Onishi
H
H
Inoue
K
K
Sugiyama
N
N
Suzuki
K
K
Yamada
Y
Y
Kosaka
K
K
D000483:Alleles; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D004247:DNA / Q000097:blood; D005787:Gene Frequency; D005838:Genotype; D006720:Homozygote; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000201:enzymology* / Q000235:genetics*; D012016:Reference Values; D012559:Schizophrenia / Q000201:enzymology / Q000235:genetics*
D004247:DNA; D019389:Cytochrome P-450 CYP2D6